Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer

Yuh Shyan Tsai, Yeong Chin Jou, Hsin Tzu Tsai, Ian Seng Cheong, Tzong Shin Tzai

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Purposes: Indoleamine-2,3-dioxygenase-1 (IDO1) is a key enzyme of tryptophan metabolism which regulates T cell function in immune cells and little is known about the role of IDO1 expression in bladder cancer cells. The study is aimed to evaluate the clinical relevance of IDO1 expression in human bladder urothelial carcinoma (UC). Materials and Methods: One hundred and sixty paraffin-embedded UC tissues (130 bladder, 30 upper urinary tract) and 47 adjacent normal tissues were retrieved for IDO1 immunostaining. Urine samples from UC and non-UC patients were collected before surgery for measuring the concentration of tryptophan and its metabolites. Clinicopathological correlates of IDO1 expression and the prognostic values in human bladder cancer were explored. External validation was performed with 4 published bladder cancer datasets, as well as in vitro studies. Results: As compared with normal adjacent tissues, UC exhibited a higher frequency of IDO1 expression (chi-square, P = 0.0005). IDO1 expression is an independent poor prognostic factor for disease progression [hazard ratio and 95% confidence interval, 3.80 (1.46–9.86), P = 0.006], which is associated with decreased number of intratumoral infiltrating CD8+ lymphocyte (unpaired t test, P = 0.026). External validation showed that patients with higher IDO1 expression exhibit decreased disease-specific survival than those with lower IDO1 expression. Furthermore, IDO1 expression correlated positively with the expression of several EMT markers, including ZEB2, fibronectin and vimentin. The in vitro T24 cell subline demonstrated that IDO1 expression can up-regulate ZEB2 expression probably through miR-200c signaling. Conclusion: IDO1 expression predicts poorer survival and up-regulates ZEB2 expression in human bladder cancer.

Original languageEnglish
Pages (from-to)810.e17-810.e27
JournalUrologic Oncology: Seminars and Original Investigations
Volume37
Issue number11
DOIs
Publication statusPublished - 2019 Nov

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer'. Together they form a unique fingerprint.

Cite this